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Introduction: Scleroderma is characterized by cutaneous manifestations that mainly affect the hands, arms and
face. As of today, there is no treatment for fibrotic skin lesions of scleroderma. Previously we generated and
validated a model of scleroderma-like skin sclerosis in nude mice, appropriate to inject human derived products.
We showed that the subcutaneous injection of micro-fat (MF), purified and injected using small caliber cannulas,
have anti-fibrotic and pro-angiogenic effects and appears more suitable for the treatment of skin lesions of
scleroderma compared to the gold standard (Coleman’s technique or macro-fat). Here we compared the long-term
efficacy of micro-fat “enriched” with other therapeutic products including the stromal vascular fraction (SVF) of fat
and platelet-rich plasma (PRP) from blood in our murine model of scleroderma.
Methods: We used 72 nude mice in this study. We formed six experimental groups: Macro-fat, MF, SVF, PRP,
MF + SVF, MF + PRP. This project has three phases: i) Induction of skin sclerosis by daily subcutaneous injections of
bleomycin (BLM) for 4 weeks in nude mice; ii) Purification and injection of the different cell therapy products;
iii) Histological analyses done 8 weeks post-injections.
Results: MF + SVF and MF + PRP significantly reversed dermal and epidermal sclerosis (P <0.01). Macro-fat, SVF,
PRP only corrected the dermal sclerosis (P <0.05). Epidermal sclerosis was reduced in treatments containing MF
(P <0.01). MF was more stable. Products containing the SVF were associated with a significant increase of the local
vascularization (P <0.01).
Conclusions: All tested substances were effective in treating skin-induced lesions of scleroderma with different
levels of fibrosis and vascular improvement; MF derived products are more stable and SVF demonstrated better
pro-angiogenic effects. The observed efficacy of this combination of products in the animal model provides a
rationale for potential clinical applications to treat human disease.Introduction
Over the years, new approaches to fat transfer – also
referred to as lipoinjection or lipofilling – have been
explored, studied extensively and refined. In 1995,
Dr Sydney Coleman developed a simple fat transfer
procedure [1], which has rapidly become the refer-
ence technique in reconstructive and cosmetic surgery.
Briefly, the procedure consists of a gentle and atraumatic
manual aspiration of the subcutaneous fat tissue, usually
in the abdomen or trochanters, using a 3 mm diameter* Correspondence: nico.serratrice@orange.fr
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unless otherwise stated.suction cannula mounted on a 10 cm3 syringe. After
a short centrifugation at 1,200 g for 3 minutes to
remove the blood, oil and tissue residuals, adipose
tissue is purified and directly reinjected subcutaneously
with a 17 G cannula. Owing to its autologous origin,
adipose tissue injection appears safe.
Experience has shown that fat transfers may have a
true regenerative effect in addition to the volumizing
effect [2]. Mature adipocytes represent only 40 to 60% of
the cells of the adipose tissue. The fat also contains the
stromal vascular fraction (SVF), within which mesen-
chymal stem cells are located. Numerous studies have
characterized the nature of the SVF stem cells. These
mesenchymal-like stem cells are able to develop in vitroal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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even hepatocyte phenotypes [3-12]. SVF also contains a
large number of fibroblasts characterized by membrane
markers CD34+ and CD90+. SVF is capable of secreting
collagen and matrix metalloproteinases and of orga-
nizing extracellular matrix [13]. In addition, SVF cells
behave as endothelial progenitors with strong angiogenic
potential [14-18]. Paracrine and autocrine effects of rein-
jected SVF cells play a major role in the dermal tissue
quality, recruiting nearby stem cells, and stimulating also
surrounding differentiated cells [19,20]. Several recent
studies have shown that fat prepared according to the
Coleman procedure mixed with the SVF increases graft
survival compared with fat alone [21-23]. This new con-
cept of fat enrichment or supercharged fat offers new
therapeutic perspectives.
However, adipose tissue obtained using the Coleman
procedure is relatively thick: it forms 1 mm diameter fat
filaments, limiting injections into subcutaneous space –
subdermal injections being relatively tricky. As a result,
an innovative technique of microinjection for adipose
tissue called microinjection has been developed in the
laboratory. The sampling and reinjection methods have
been modified to obtain micro-fat (MF), more fluid,
which can be injected through smaller needles [24].
The technique involves removal and purification of
MF by gentle suction with a 1 mm diameter micro-blunt
cannula with multiple holes mounted on a 10 cm3
syringe and by a short centrifugation at 1,200 g/minute
for 2 minutes. MF is composed of micro-adipocyte
lobules (around 500 μm) that can be reinjected through
a 21 G cannula (0.8 mm).
Scleroderma is a chronic systemic autoimmune disease
primarily of the skin (‘derma’) characterized by fibrosis
or hardening (‘sclero’), vascular alterations, and autoanti-
bodies [25,26]. Various cutaneous manifestations are
possible in scleroderma (morphea, en coup de sabre). At
present, there is no consensus treatment for skin lesions
of scleroderma and injection of adipose tissue could
represent a viable option. We previously compared the
efficacy of injection of fat prepared according to the
Coleman procedure versus MF in a nude mice model of
scleroderma [27]. We evidenced histologically that the
MF injection was more efficient than fat injection in
reducing bleomycin (BLM)-induced injury, as shown by
reduction of dermis thickness (P <0.05 with Coleman’s
technique and P <0.01 with the technique of microinjec-
tion) and improved vascularization of the deep dermis
and subcutis (P <0.01). Otherwise, these results are con-
sistent with previously reported clinical data for localized
scleroderma [28,29] as well as other skin lesions [30].
Hence, fat microinjection appeared more suitable for
injection or subdermal fibrotic tissue. However, no study
has investigated whether enriching MF with SVF couldoptimize the therapeutic potential of this procedure in
scleroderma.
The use of platelet-rich plasma (PRP) represents another
attractive option for the development of combined bio-
logical therapy. Owing to its capacity to deliver various
growth factors, PRP has been investigated as a regene-
rative treatment in various conditions including nerve in-
jury, tendinitis, osteoarthritis, cardiac muscle injury, bone
repair and regeneration, plastic surgery, maxillofacial and
oral surgery [31-35]. Various in vitro studies indicate that
PRP may have beneficial impact on the regenerative po-
tential of mesenchymal stem cells [36]. However, very few
studies have examined the use of a fat mixture (prepared
according to Coleman) and PRP. In 2012, Gentile and
colleagues reported that a fat + PRP mix increases graft
survival compared with fat alone, thus maintaining a
volumizing effect in breast reconstruction [22]. No study
has been conducted on a MF + PRP mix.
This study was conducted to evaluate and compare
efficacy of these different cell therapy products – macro-fat
(Coleman’s procedure), MF, SVF, PRP, MF + SVF and
MF + PRP – in the nude mice model of skin-induced
lesions of scleroderma. A beneficial effect of fat grafting on
the sclerotic skin should have potential clinical applications
to treat human disease or other soft tissue defects.
Methods
Animals
The National Animal Care and Ethics Committee
approved the care of mice and the experimental proce-
dures (#00506.02). Based on the results of previous
work, we determined that six mice/group would be suffi-
cient to show a statistically significant difference between
the different cell therapy products. Seventy-two pathogen-
free female nude mice (6 weeks old, weight ~20 g) were
purchased from Charles River Laboratories (L’arbresle,
France). Forty-eight nude mice were used for the experi-
ment, and 24 mice as controls. The experiment was
conducted in the new A2 animal facility of the Centre
de Formation et de Recherches Expérimentales Médico-
Chirurgicales of the Faculty of Medecine of Marseilles.
Mice were acclimated for 3 weeks before any experi-
mental procedures. No mice died prematurely during
experimentation.
Bleomycin treatment
BLM treatment was specially adapted from Yamamoto’s
original protocol for nude mice [27,37]. Briefly, BLM
(Sanofi-Aventis, Paris, France) was dissolved in 0.9% so-
dium chloride saline solution at a concentration of 300
μg/ml. Forty-eight mice (9 weeks old) were injected sub-
cutaneously into three different shaved parts known to
have the same skin thickness – the interscapular region
and both flanks – with a volume of 100 μl (30 μg) BLM,
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weeks. Mice were housed for one additional week with-
out any treatment for recovery before injections of the
different cell therapy products under general anesthesia.
In parallel, 12 mice were injected in the same sites
with 100 μl of 0.9% sodium chloride saline solution for 4
weeks and were housed for one additional week without
further treatment. Twelve supplementary naive mice for
all treatments were used as negative controls.
Skin sclerosis was evaluated at 5 and 13 weeks by histo-
logical analyses on 12 mice randomly selected from the 48
BLM-treated mice, the 12 sodium chloride-treated mice
and the 12 control mice (n = 6 for each time point).
Experimental groups
Six experimental groups of six nude mice were randomly
constituted (Table 1).
Cell therapy products
A single, healthy volunteer donor was included after in-
formed consent. All of the cell therapy products were
purified and injected on the same day. This study did
not need ethical approval for the use of human-derived
products for research, because fat was considered surgi-
cal waste and no genetic research was carried out. Fat
(according to Coleman’s method) and MF were collected
from the lateral abdomen/flank areas during an abdom-
inal dermolipectomy as described above. During the
intervention, peripheral whole blood was taken at the
elbow. The donor had no relevant diseases and was free
of any drugs known to affect platelet functions for 7 days
before the study. Standard serological tests were per-
formed on whole blood for the safety of manipulations.
All procedures were conducted under a class A microbio-
logical safety facility located in the Culture and Therapy
Unit at La Conception Hospital (Assistance Publique –
Hôpitaux de Marseille), Marseilles, France.
Coleman’s technique
Fat was aspirated gently with a manual and nontraumatic
technique, using Coleman’s blunt cannula (length 15 cm,Table 1 Experimental conditions and composition for
each cell therapy product
Group Cell therapy products Compositions
1 Coleman (gold standard) 0.5 cm3
2 MF 0.5 cm3
3 SVF 0.5 cm3 RL + 0.0114 cm3 SVF
4 PRP 0.25 cm3 PPP + 0.25 cm3 PRP
5 MF + SVF 0.5 cm3 MF + 0.0114 cm3 SVF
6 MF + PRP 0.25 cm3 MF + 0.25 cm3 PRP
Final volume/mouse = 0.5 cm3. MF, micro-fat; PPP, platelet-poor plasma;
PRP, platelet-rich plasma; RL, Ringer’s lactate; SVF, stromal vascular fraction.internal diameter 2.42 mm; that is, 11 G) mounted with a
10 cm3 syringe.
Stromal vascular fraction
Fat (220 cm3) was aspirated according to Coleman’s tech-
nique. SVF was purified with the Celution® system (Cytori
Therapeutics, San Diego, California, USA) following the
recommended instructions. This system has been the sub-
ject of numerous publications in the areas of myocardial
ischemia [38-41].
Micro-fat
MF (18 cm3) was aspirated with a cannula (length 15 cm,
internal diameter 1 mm; that is, 14 G) mounted with a 10
cm3 Luer Lock syringe. MF was purified after a short cen-
trifugation (1,200 × g during 3 minutes) with a microcentri-
fuge (Medilite®, Ref. 448; Thermo Scientific, Waltham,
Massachusetts, USA) to eliminate oily and bloody residues.
Platelet-rich plasma
PRP was produced according to a previously described
methodology [42]. Briefly, 68 cm3 whole blood were
collected in eight 10 cm3 tubes (Vacuette®, Ref. 455001;
Greiner Bio-One, Monroe, North Carolina, USA) with
1.5 cm3 adenosin citrate dextrose-acid solution (ACD-
A®, Ref. BDB8651; Fenwal Inc., Portland, Oregon, USA),
making 80 cm3. Another tube, coated with the ethylene-
diamine tetraacetic acid anticoagulant, was used to deter-
mine the platelet number and concentration with an
automatic cell counter (ADVIA® 2120; Siemens Diagnostic
Solutions, Malvern, Pennsylvania, USA). A first spin at
130 × g during 15 minutes and a second spin at 250 × g
during 15 minutes in eight 11 cm3 conic tubes (NUNC®,
Ref. 56423; Thermo Scientific, Waltham, Massachusetts,
USA) were performed in a standard laboratory microcen-
trifuge (Medilite®, Ref. 448; Thermo Scientific). Super-
natant or platelet-poor plasma (PPP) was removed by
gentle aspiration (approximately 1 cm3/tube). PRP pellets
were resuspended in the residual PPP and pooled. At final
measurement, we obtained a total of 8.5 cm3 concentrated
PRP. An approximately 250 μl sample was used to deter-
mine the PRP final formulation with an automatic cell
counter (ADVIA® 2120; Siemens Diagnostic Solutions).
Mixes
The MF + SVF and MF + PRP compositions are reported
in Table 1.
For each product, about 100 μl were injected into
pediatric blood culture bottles (BacT/ALERT® device;
bioMérieux, Craponne, France). Under these conditions,
we obtained controlled and optimized cell therapy prod-
ucts. All products were packaged in 1 cm3 syringes for
subsequent use. Ringer’s lactate was used to resus-
pend SVF and PPP for PRP.
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Under general volatile anesthesia (isoflurane (Forène®,
Baxter France, Maurepas, France), concentration 2.5 to
3%, flow 400 to 600 ml/minute), a 1 mm incision was
made on the external side of each thigh in view to intro-
duce a 21 G blunt cannula for the MF, SVF, PRP, MF +
SVF and MF + PRP injections. Macro-fat was injected
using the classical Coleman’s procedure. One flank was
injected with cell therapy products, whereas the other side
was injected with the suitable resuspension product
(Ringer’s lactate for SVF, and PPP for PRP) and served as
the injection control. One-half of the mice in each experi-
mental group received cell therapy products on the left
and resuspension products on the right, and the other half
received the contrary. The injection volume was 0.5 cm3
for all cell therapy products. Details of the different
injected products are presented in Table 1. The total ex-
perimental duration was 8 weeks (2 months or 56 days);
that is, mice were sacrificed at 22 weeks of age.
Histological examination
Blinded histological analyses were conducted by a skin path-
ologist. A semiquantitative evaluation was used to evaluate
cell therapy product viability during skin removal (0, no
trace of the product; +, trace of the product; ++, cell therapy
product still present). Skins were fixed in 10% formalin solu-
tion and embedded in paraffin. Then 5 μm thick sections
were stained with hematoxylin and eosin, Masson’s tri-
chrome, and orcein stainings to evaluate histopathological
changes and to detect collagen fibers in tissues, and
with toluidine blue staining to identify mast cells. Sections
were examined using a light microscope (Axiophot; Zeiss,
Oberkochen, Germany) and photographed with a digital
camera. Epidermal and dermal thicknesses were measured
quantitatively. Distances were calculated using GraphPad
software (GraphPad, La Jolla, California, USA). Six measures
were made and means were compared for each experi-
mental condition. A semiquantitative evaluation was per-
formed to evaluate vascularization (0, capillaries present in
normal number and morphology; +, increased number of
congested capillaries; ++, numerous congested capillaries).
Statistical analyses
Statistical analysis was performed on Statview software
(Statview, Cary, North Carolina, USA). Results are expressed
as mean ± standard deviation. Significance testing was per-
formed using analyses of variance. P <0.05 was considered
significant.
Results
Pathological and clinical manifestations of the skin-induced
model of scleroderma
Repetitive sodium chloride injections did not induce skin
sclerosis (data not shown). Dermis and epidermis afterinjection had the same thickness as untreated mice; skin
of both flanks and the interscapular region also had the
same thickness (mean dermal thickness = 156 ± 3 μm;
mean epidermal thickness = 12 ± 1 μm; mean total skin
thickness = 168 ± 3 μm; n = 12). Epidermis was around
one-tenth of dermal thickness. Only untreated and BLM-
treated mice are represented in Figure 1.
On the contrary, daily BLM subcutaneous injections
during 1 month induced stable skin sclerosis (evaluated
at 5 and 13 weeks post BLM treatment). Macroscopic-
ally, injection sites appeared thicker and indurated to the
touch (Figure 1b, macroscopic picture). After incision, the
skin showed a whitish and bright aspect compatible with
sclerosis. Histopathological examination (hematoxylin
and eosin) showed that all BLM-treated sites developed
a stable sclerosis (mean dermal sclerosis = 198 ± 20 μm;
mean epidermal sclerosis = 20 ± 3 μm; mean total skin
sclerosis = 218 ± 20 μm; n = 12, P <0.01) (Figure 1c,d,e)
compared with healthy skin (Figure 1a). Sclerosis is
characterized by a global and homogeneous increase in
the total skin thickness (the ratio epidermal/dermal
sclerosis was one-tenth), a decrease in the amount of
subcutaneous fat tissue (Figure 1b, histological picture),
and a deposition of homogeneous materials in the thick-
ened dermis. Masson’s trichrome and orcein stainings
revealed a dense collagen network, and elastic fibers ap-
peared more abundant and dense in the thickened der-
mis in BLM-treated skin than in control skin (data not
shown). Toluidine blue staining revealed that there was
no difference in mast cell number or morphology after
BLM treatment (data not shown). These were the same
histopathological features reported previously for skin
fibrosis [27,37]. Mononuclear cells were rare or absent
in all analyzed skin, which was expected in nude mice.
At the end of BLM treatment, the body weights of the
BLM-treated mice (fifth week; that is, 14-week-old mice)
were significantly decreased (Figure 1f) compared with
untreated mice. Cytotoxic effects of BLM may contribute
to the break in the growth curve. The time course of body
weight loss continued during the experiment (13th week;
that is, 22-week-old mice) but did not affect the nude
mice viability.
Characterization and injection of the different cell
therapy products
Stromal vascular fraction
From 220 cm3 harvested fat, we obtained 5.2 cm3 SVF
with 11,530,000 cells/cm3, corresponding to 131,000 cells
injected/mouse (0.0114 cm3).
Platelet-rich plasma
From 63 cm3 blood, we obtained 8.5 cm3 PRP with a plate-
let concentration of 512 G/l and 8.5 cm3 PPP. PRP was di-
luted into PPP for injections, (0.25 + 0.25) 1.28 G/l or 0.64
Figure 1 Skin-induced sclerosis after bleomycin treatment. Because of their inherent fragility, nude mice were injected subcutaneously with
30 mg bleomycin (BLM)/site daily during 1 month (both flanks and neck). Mice injected with 0.9% sodium chloride (NaCl) saline solution presented the
same characteristics as untreated mice; only the control mice are represented. (a) Healthy skin (hematoxylin and eosin). (b) Fibrotic skin changes
observed after BLM treatment. Macroscopically, injection sites appeared thicker and indurated to the touch (macroscopic picture, red ellipses).
Histological analyses of BLM injection sites showed a global increase in skin thickness, and a decrease in the amount of subcutaneous fat tissue
(histological picture). Comparison of (c) the dermis, (d) the epidermis and (e) the total skin thickness at the end of the BLM treatment (5 weeks). Data
presented as mean ± standard deviation (**P <0.01, control mice n = 6, BLM-treated mice n = 6). (f) Time course of body weight (grams) (**P <0.01,
control mice + NaCl-treated mice n = 24, BLM-treated mice n = 48). A break in the growth curve was observed at the end of BLM treatment (fifth week)
and during all of the experiment (13th week). Bars = 250 μm. White, BLM-untreated mice; black, BLM-treated mice.
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PRP formulation. This formulation was similar to that
previously reported for PRP purification [42,43].
All microbiological tests returned sterile. Composition
of the different cell therapy products are presented inTable 2 Platelet-rich plasma formulation
Blood cells Concentration Cell number/mouse
Platelets 512 G/l 1,280,000,000
Red blood cells 0.13 T/l 325,000,000
White blood cells 0.88 G/l 220,000
Lymphocytes 0,75 G/l 187,500
Monocytes 0.07 G/l 17,500
Polynuclear neutrophils 0.06 G/l 15,000
Polynuclear eosinophils 0 G/l 0
Polynuclear basophils 0 G/l 0Table 1. Injections were made within 30 minutes after
purification. Short general anesthesia and injections were
well tolerated by animals.
Clinical changes after treatment
Globally, sclerosis treated with the different cell ther-
apy products appeared less thick and less indurated
to the touch than untreated or treated sites with the
appropriate dilution products, but this was generally
difficult to assess. After sacrifice and during skin
removal, donor fat tissue was still present in each of
the three groups that included MF-derived products
(that is, MF, MF + SVF and MF + PRP). MF formed
homogeneous fat nodules, adherent under the skin
sclerosis. We found macro-fat (Coleman’s procedure)
in only one of the six mice without adhesion to the
injured skin. On the contrary, we have found no trace
of PRP or SVF products.
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The injection of the appropriate dilution products (that
is, Ringer’s lactate for SVF, PPP for PRP, and sodium
chloride for other conditions) had no effect on sclerosis
(negative control of injections checked). These injection
control sites were used to compare the efficacy of the
different cell therapy products on sclerosis. A significantFigure 2 Effects of the different cell therapy products. (a) Dermal, epid
as mean ± standard deviation (n = 6, six measures/mouse). (b) Graphic repr
healthy skin (no bleomycin (BLM), no treatment); grey, sclerosis control (BL
(NaCl)); black, treatments (BLM + cell therapy products). (c) Corresponding
stromal vascular fraction.reduction of sclerosis was reported according to the
treatment. Data for dermal, epidermal, and total skin
thickness for each treatment are shown in Figure 2a.
With MF + SVF and MF + PRP we observed significant
reduction of the dermal and the epidermal sclerosis
induced by BLM treatment (P <0.01) (Figure 2b). Macro-
fat (Coleman’s procedure), SVF and PRP only correctedermal and total skin thicknesses were measured (μm). Data presented
esentation of the total skin thickness (*P <0.05, **P <0.01). White,
M, no treatment); dark grey, injection control (BLM + sodium chloride
histology. Bars = 500 μm. MF, micro-fat; PRP, platelet-rich plasma; SVF,
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duced in treatments containing MF (P <0.01). In terms of
collagen and elastic fibers observed in hematoxylin and
eosin (Figure 2c) and Masson’s trichrome (data not
shown), deposits in the dermis were still present and it
was difficult to quantify and compare histologically the
efficiency of the different cell therapy products. Further
biochemical investigations should be conducted to better
evaluate the impact of the different cell therapy products
on collagen architecture and the elastic fiber density.
There was no evidence of an immune response between
the host animal and the grafted human material (either as
rejection or graft versus host reaction).Fat graft viability
MF-derived products were still present at the end of the
experiment (Figure 3a); that is, 8 weeks post injections.
MF formed homogeneous and adherent fat nodules under
the panniculus carnosus. Figure 3b presents the biggest
MF nodule observed. With GraphPad software, we ob-
tained the two-dimensional dimensions: length 4,492 μm
and thickness 1,495 μm. We extrapolated and calculated
the approximate three-dimensional volume as around
0.03 cm3, which represents 6% of the injected initial
volume.Evaluation of dermal blood vessels
Blood vessel appearance and density in areas treated with
MF, PRP, or MF + PRP showed no difference from control
(Figure 3a). By contrast, skin treated with either SVF alone
or the combination of SVF +MF showed a significant
increase of the vessel density (Figure 3a, P <0.01). VesselsFigure 3 Fat graft viability and vascularization (a). (b) Example of a mi
months post injection (hematoxylin and eosin). Bars = 500 μm. Evaluation o
(c) Number of congested capillaries (mean of capillary diameters = 19.6 μm), i
and eosin, P <0.01). Bars = 200 μm.in these groups had a congested aspect, with an estimation
of their mean diameter around 19.6 μm (Figure 3c).
Discussion
The current study demonstrated the efficacy of six dif-
ferent restorative biotherapies on skin-induced lesions of
scleroderma. MF + SVF and MF + PRP significantly re-
versed dermal and epidermal sclerosis that developed
after BLM treatment (P <0.01). Macro-fat (Coleman’s
procedure), SVF, and PRP only corrected the dermal
sclerosis (P <0.05). Epidermal sclerosis was reduced in
treatments containing MF (P <0.01). MF-derived prod-
ucts were still present 8 weeks post injections. SVF
products were associated with a significant increase of
the local vascularization. Hence, MF-derived products
were more stable and SVF demonstrated a better proan-
giogenic effect.
The regenerative effect appears to be associated with
the duration of graft viability. Once the graft was placed
in its new location, survival appeared dependent on the
growth of new blood vessels in the transplanted fat frag-
ments, resulting in a permanent correction of the treated
site. In this context, the restoration of blood flow ap-
peared essential to the survival of the graft. Grafting
techniques that do not facilitate vascular development
generally caused a partial or total loss of the adipose tis-
sue graft and only obtained a short-term effect requiring
repeated injections to obtain satisfactory results.
After sacrifice and during skin removal, we found no
trace of PRP or SVF products, leading us to suppose that
these products have been degraded. Nevertheless, PRP
and SVF are known for their proangiogenic properties
and they probably improve the environment of the graft,cro-fat (MF) nodule (dimensions 4,492 μm× 1,495 μm) still present at 2
f the MF graft size suggested retention of ~6% of initial volume.
ncreased with stromal vascular fraction-derived products (hematoxylin
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tissue are too poor in their natural state to allow survival
and function of the transplanted graft. Indeed, PRP or
SVF cells are fragile, and even if they have proangiogenic
properties, they are not able to survive over the long
term. On the contrary, we observed that products con-
taining MF were still present 8 weeks post injections.
MF seems to offer favorable conditions for grafting
and survival of associated PRP or SVF cells. Moreover,
the number of vessels observed in the dermis was sig-
nificantly increased in the SVF or MF + SVF groups,
compared with the others. MF offers ideal conditions for
SVF cell survival and thus may improve vascular disor-
ders encountered in scleroderma. These data are similar
to the work by Fumimoto and colleagues reporting that
the creation of a rich subcutaneous vascular network
with implanted adipose tissue-derived stromal cells and
adipose tissue enhances subcutaneous grafting of islets
in diabetic mice [44]. Hence, MF and SVF could provide
superior benefits over the long term compared with
either agent alone. SVF should normalize the balance of
local profibrotic and antifibrotic factors and increase the
microvascular network, thereby improving the skin-
induced lesions of scleroderma, as suggested by the ob-
servations in this study.
It is hypothesized that when PRP is mixed with MF,
the MF immediately activates the PRP, causing platelet
degranulation and the release of cytokines and growth
factors. This may activate MF stem cells leading to re-
generative properties, and thereby allow repair of the
skin-induced lesions of scleroderma. In addition, it ap-
pears that short-term effects cannot reverse epidermal
lesions, and that long-term treatment may be required
to reverse epidermal lesions. The final consideration for
graft survival is the immune system response. To bypass
the problem of histocompatibility, we used nude immu-
nodeficient mice. Extrapolation to human studies is
therefore limited.
Several open issues remain unanswered. Optimal dosing
is unclear and minimal data have been published in this
area. Another issue inherent to preparation of PRP prod-
ucts is that there are many techniques available, in terms
of preparation (centrifugation speed, use of anticoagulant)
and content (platelets, leukocytes, growth factors) for PRP
applications. All these aspects are discussed in the litera-
ture but there is no consensus on the optimal approach.
To add to the complexity, PRP content varies from one
individual to another and within the same individual over
the time, leading to contrasting in vivo effects. For this
reason, the development of autologous formulations with
a controlled platelet count, and consequently a controlled
bioactive factor release, appears necessary [43]. In the
present study, we injected 0.64 million platelets and
131,000 cells from the SVF per mouse. Evaluation ofdifferent doses to determine the optimal PRP formulation
to use in vivo is warranted.
These data represent preliminary results. Biochemical
assays (collagen, growth factors), mass spectrometry, im-
munological assays (cytokines) and proliferative tests of
fibroblasts would be a logical next step to better under-
stand the mechanisms involved in the observed tissue
regeneration.
Separately, PRP and SVF have short-term effects,
implying that repeated injections would be necessary to
obtain satisfactory results. MF and derived products are
capable of long-term viability, limiting the number of
injections. We highlighted the interest of MF + SVF and
MF + PRP mixtures compared with the MF, SVF and
PRP separately for treating skin-induced lesions of sclero-
derma. Based on the study results, we cannot discriminate
the efficacy of MF + SVF compared with MF + PRP. The
only difference is that MF + SVF treatment contains more
blood vessels than MF + PRP, suggesting a superior proan-
giogenic property and consequently a superior envi-
ronment for graft survival. The use of these different
regenerative products was the potential for a viable option
to improve the treatment of soft tissue defects, such as
scleroderma observed in human patients.
At present, there is no consensus regarding treatment
for skin lesions of scleroderma. Mild forms are treated
with corticosteroids for a short period (to limit the side
effects associated with prolonged corticosteroid therapy).
Therapeutic abstention may also be an alternative, given
the lack of evidence of the effectiveness of a particular
treatment. Immunosuppressive medications are consid-
ered for severe or systemic forms, but have very limited
efficiency on the skin lesions. No antifibrotic treatment
is known to improve skin fibrosis in this disabling disease,
and thus far there is no drug that specifically reverses
the microvascular injury or acts on both components
together.
Fat grafting has proven to be efficient and well toler-
ated in the treatment of localized forms of scleroderma
such as en coup de sabre scleroderma [45], but it has
never been used to treat scleroderma skin lesions. Hand
lesions are also a major problem in this disease, involving
phenomena of vascular origin (ischemia), fibrotic skin
lesions (scarring skin of the fingers and backs of hands)
and subcutaneous calcinosis. This symptomatology has
major functional consequences (pain, loss of function) and
integumentary (sclerodactyly, ulcer, infection and gan-
grene). For scleroderma involving the hands, the volumiz-
ing effect is not desired and only the trophic effect is
necessary to justify the injection of autologous SVF. The
SVF is a pure condensed form of multipotent stem cells,
and combined with their mechanical properties (fluidity,
small amount) the cells appear suitable for treatment of
fingers. The current results provide a rationale for a clinical
Serratrice et al. Stem Cell Research & Therapy 2014, 5:138 Page 9 of 10
http://stemcellres.com/content/5/6/138study of fat-derived products for patients with sclero-
derma skin lesions, particularly those involving the hands.
Conclusions
The current study demonstrates the efficacy of six differ-
ent restorative biotherapies on skin-induced lesions of
scleroderma. MF + SVF and MF + PRP significantly re-
versed dermal and epidermal sclerosis developed after 1
month of BLM treatment (P <0.01). Macro-fat (Coleman’s
procedure), SVF, and PRP only corrected the dermal scler-
osis (P <0.05). Epidermal sclerosis was reduced in treat-
ments containing MF (P <0.01). MF-derived products
were still present 8 weeks post injections. SVF products
are associated with a significant increase in the local
vascularization. Hence, MF-derived products are more
stable and SVF demonstrated a better proangiogenic
effect. The observed efficiency of these combination prod-
ucts in the animal model provides a rationale for potential
clinical applications to treat human disease.
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